Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist currently in Phase 3 trials
Research Use Only Important Legal Notice Used solely for in vitro experiments and cannot be: Used in clinical trials involving humans Administered to humans as part of an experiment or investigation, Supplied to another party for human investigational use
In severe cases of deficiency, our experienced healthcare providers may recommend an initial treatment plan that involves frequent injections, potentially daily or every other day, for one to two weeks
In simple terms, growth hormone has a region near one end of its molecule that signals fat cells to release stored fat
If targeting 2.5mg per dose, add 5mL instead to create a 10mg/mL solution
It cannot prove that an unlisted research product is safe